UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Income Statement [Abstract]
Revenue, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Oncology services revenue	$ 13,489	$ 11,573	$ 27,550	$ 24,134
Costs and operating expenses:
Cost, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Cost of oncology services	$ 7,428	$ 6,618	$ 14,500	$ 14,302
Research and development	1,689	2,515	3,143	5,308
Sales and marketing	1,751	1,795	3,430	3,491
General and administrative	1,889	2,600	4,416	5,540
Total costs and operating expenses	12,757	13,528	25,489	28,641
Income (loss) from operations	732	(1,955)	2,061	(4,507)
Other income (expense)	7	(105)	11	(91)
Income (loss) before provision for income taxes	739	(2,060)	2,072	(4,598)
Provision for income taxes	11	11	31	39
Net income (loss)	$ 728	$ (2,071)	$ 2,041	$ (4,637)
Net income (loss) per common share outstanding
basic (in dollars per share)	$ 0.05	$ (0.15)	$ 0.15	$ (0.34)
and diluted (in dollars per share)	$ 0.05	$ (0.15)	$ 0.15	$ (0.34)
Weighted average common shares outstanding
basic (in shares)	13,593,766	13,497,061	13,593,766	13,529,629
and diluted (in shares)	14,016,953	13,497,061	14,029,666	13,529,629